| Basics |
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
|
| IPO Date: |
December 7, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$887.96M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 2.82%
|
| Avg Daily Range (30 D): |
$1.68 | 4.26%
|
| Avg Daily Range (90 D): |
$1.16 | 3.23%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.99M |
| Avg Daily Volume (30 D): |
.56M |
| Avg Daily Volume (90 D): |
.61M |
| Trade Size |
| Avg Trade Size (Sh.): |
224 |
| Avg Trade Size (Sh.) (30 D): |
51 |
| Avg Trade Size (Sh.) (90 D): |
56 |
| Institutional Trades |
| Total Inst.Trades: |
1,749 |
| Avg Inst. Trade: |
$1.4M |
| Avg Inst. Trade (30 D): |
$2.27M |
| Avg Inst. Trade (90 D): |
$1.85M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.57M |
| Avg Closing Trade (30 D): |
$2M |
| Avg Closing Trade (90 D): |
$2.01M |
| Avg Closing Volume: |
56.07K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$6.34
|
$1.55
|
$3.33
|
|
Diluted EPS
|
$6.18
|
$1.46
|
$3.28
|
|
Revenue
|
$ 282.08M
|
$ 69.46M
|
$ 101.69M
|
|
Gross Profit
|
$ 262.62M
|
$ 64.71M
|
$ 97.18M
|
|
Net Income / Loss
|
$ 113.3M
|
$ 27.9M
|
$ 59.61M
|
|
Operating Income / Loss
|
$ 118.95M
|
$ 28.42M
|
$ 61.1M
|
|
Cost of Revenue
|
$ 19.46M
|
$ 4.75M
|
$ 4.5M
|
|
Net Cash Flow
|
$ -3.1M
|
$ -4.87M
|
$ 7.68M
|
|
PE Ratio
|
7.05
|
|
|
| Splits |
|
Jun 27, 2024:
1:10
|
|
Jun 25, 2003:
1:9
|
|
|
|
